Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,183.3
-22.2 (-0.69%)

 

  • STI Straits Times Index
    3,183.3
    -22.2 (-0.69%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,603.7
    -1.6 (-0.10%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    27,657.2
    -130.4 (-0.47%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,906.0
    35.4 (1.23%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    21,272.5
    -29.3 (-0.14%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    5,951.4
    44.3 (0.75%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,061.2
    5.5 (0.27%)
    Index delayed 20 minutes
  • XAO XAO
    6,584.4
    19.7 (0.30%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 754.6M
  • Value: 1,169.5M
  • Rise: 90
  • Fall: 240
  • Unch: 510

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
JCG Investment0.002-
Genting Sing0.880-0.010
YZJ Shipbldg SGD1.440-0.030
NetLink NBN Tr0.845-
Nico Steel^0.004-0.001
MDR0.002+0.001
ESR-REIT0.540+0.010
Thomson Medical0.062-0.004
SingTel3.140-
ThaiBev0.785+0.005

World Indices

World Indices
Name Last Change
Nasdaq 7,702.4 -113.9
HSI 27,657.2 -130.4
HSCEI 10,634.6 +1.2
Jakarta 5,951.4 +44.2
Nikkei 225 21,272.5 -29.3
SSE Comp 2,906.0 +35.4
Shanghai A 3,043.5 +37.0
Shanghai B 293.1 +3.5
ShenZhen A 1,619.7 +28.2
ShenZhen B 947.1 +11.6
Taiwan W 10,464.5 +66.1
PSE Comp 0.0
KOSPI 2,061.2 +5.5

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Tianjin ZX USD TIANJIN ZHONG XIN PHARM GROUP
Quotes 10 Minutes Delayed. Updated at 21 May 2019 17:04
Last (USD): 0.915 Change: -0.005 High: 0.925 Remarks: -
Change (%): -0.54 Low: 0.915
Open 0.920 Yesterday's Close 0.920
Buy Price 0.915 Sell Price 0.920
Buy Volume ('000) 27.1 Sell Volume ('000) 11.8
Cumulative Volume ('000) 152.3 Cumulative Value 140,199
Click to show Stock Prices chart

Key Statistics

EPS (USD) a 0.10622 Trailing EPS (USD) e 0.31751 NAV (USD) b 6.6652
PE a 8.614 Trailing PE f 2.882 Price / NAV b 0.1373
Dividend (USD) d 0.031988 Cash In Hand (USD) g 1.9066 Issued & Paid-up Shares c 200,000,000
Dividend Yield (%) d 3.496 Price / Cash In Hand g 0.480 Treasury Shares h -
Beta - 75 Daysi 1.283 R-Squared - 75 Days(%)i 26.04 Market Cap (M) 703.519
Beta - 500 Daysi 0.786 R-Squared - 500 Days (%)i 9.47 Enterprise Value (M) -497.494
Piotroski F Score 7 Exchange Code T14 Par Value ( RMB ) 1.00000
52 Weeks Volatility (%) 28.7848 6-Month VWAP 0.931 Free Float (%) 92.5
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Manufacturing - Pharmaceuticals: Other
Category Classification China / Medical & Biotechnology
Index Components FTSE ST All-Share Index / FTSE ST China Index / FTSE ST Fledgling Index / FTSE ST Health Care Index / FTSE ST Small Cap Index
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 30 Apr 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Tianjin ZX USD SGX 703.519 8.614 2.882 0.1373 3.496
Industry China SGX 655.247 17.733 23.890 0.7563 3.421
Medical & Biotechnology SGX 1,006.166 22.409 19.623 1.0872 1.915
Pharmaceuticals: Other SGX 548.621 11.275 3.301 0.1550 3.085
Index FTSE ST All-Share Index SGX 5,394.204 15.521 16.215 1.1501 3.668
FTSE ST China Index SGX 3,389.853 9.392 9.229 0.5924 3.607
FTSE ST Fledgling Index SGX 84.158 32.994 22.861 0.5332 3.026
FTSE ST Health Care Index SGX 862.889 16.526 9.030 0.5183 2.489
FTSE ST Small Cap Index SGX 657.667 9012.463 15.463 0.7995 5.846
Local Peer IX Biopharma SGX 128.919 - - 5.4201 -
Global Peer AURORA CANNABIS INC NYSE 8,589.757 151.661 - - -
Global Peer BAUSCH HEALTH COMPANIES INC NYSE 8,504.585 - - 2.4434 -
Global Peer SAGE THERAPEUTICS INC NASDAQ 8,358.095 - - 6.3341 -
Global Peer JAZZ PHARMACEUTICALS PLC NASDAQ 7,837.916 17.531 16.117 2.8706 -
Global Peer FOSUN PHARMA HKEx 61,253.334 19.097 19.202 1.8258 1.565
Global Peer ICON NASDAQ 7,409.825 22.965 22.261 5.2102 -
Global Peer PERRIGO COMPANY PLC NYSE 6,742.434 51.469 59.144 1.1828 1.532
Global Peer CATALENT INC NYSE 6,611.090 79.080 44.370 4.0792 -
Global Peer SH PHARMA HKEx 43,597.707 9.484 9.323 0.9306 3.118
Global Peer AMARIN CORP ADR EACH REP 1 ORD GBP0.50 NASDAQ 5,564.671 - - 46.7500 -
Other Global Peers GW PHARMACEUTICALS ADS EA REPR 12 ORD GBP0.00 (NASDAQ), CRONOS GROUP INC (NASDAQ), ARGENX SE SPON ADR EACH REP 1 ORD SHS (NASDAQ), HORIZON THERAPEUTICS PLC (NASDAQ), Kalbe Farma Tbk. (IDX), UNITED THERAPEUTICS CORP (NASDAQ), LUYE PHARMA (HKEx), INTERCEPT PHARMACEUTICALS INC (NASDAQ), MEDICINES CO (NASDAQ), SSY GROUP (HKEx), LIVZON PHARMA (HKEx), MYOKARDIA INC (NASDAQ), HEC PHARM (HKEx), SIHUAN PHARM (HKEx), PORTOLA PHARMACEUTICALS INC (NASDAQ), AERIE PHARMACEUTICALS INC (NASDAQ), PACIRA BIOSCIENCES INC (NASDAQ), IRONWOOD PHARMACEUTICALS INC (NASDAQ), SUPERNUS PHARMACEUTICALS INC (NASDAQ), TONG REN TANG (HKEx), ZOGENIX INC (NASDAQ), MADRIGAL PHARMACEUTICALS INC (NASDAQ), PRESTIGE CONSUMER HEALTHCARE INC (NYSE), INNOVIVA INC (NASDAQ), HEXO CORP (NYSE American), ENDO INTERNATIONAL PLC (NASDAQ), Kimia Farma (Persero) Tbk. (IDX), CORCEPT THERAPEUTICS INC (NASDAQ), THERAVANCE BIOPHARMA INC (NASDAQ), BLACKMORES LTD (ASX), MALLINCKRODT PLC (NYSE), CLINUVEL PHARMACEUTICALS LTD (ASX), AMPHASTAR PHARMACEUTICALS INC (NASDAQ), MEGA (SET), Indofarma Tbk. (IDX), ANI PHARMACEUTICALS INC (NASDAQ), INTERSECT ENT INC (NASDAQ), EAGLE PHARMACEUTICALS INC (NASDAQ), CANNTRUST HOLDINGS INC (NYSE), AXSOME THERAPEUTICS INC (NASDAQ), ARQULE INC (NASDAQ), FUDANZHANGJIANG (HKEx), APHRIA INC (NYSE), CONSUN PHARMA (HKEx), ANIKA THERAPEUTICS INC (NASDAQ), Tempo Scan Pacific Tbk. (IDX), REVANCE THERAPEUTICS INC (NASDAQ), BIOSPECIFICS TECHNOLOGIES CORP (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), ELIXINOL GLOBAL LTD (ASX), ALBIREO PHARMA INC (NASDAQ), MEI PHARMA INC (NASDAQ), COLLEGIUM PHARMACEUTICAL INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), BIODELIVERY SCIENCES INTERNATIONAL (NASDAQ), CATALYST PHARMACEUTICALS INC (NASDAQ), ASSEMBLY BIOSCIENCES INC (NASDAQ), SHANDONG XINHUA (HKEx), ZYNERBA PHARMACEUTICALS INC (NASDAQ), MARINUS PHARMACEUTICALS INC (NASDAQ), CERECOR INC (NASDAQ), CELYAD ADS EACH REPR 1 ORD (NASDAQ), ACELRX PHARMACEUTICALS INC (NASDAQ), ACLARIS THERAPEUTICS INC (NASDAQ), OCI INTL (HKEx), INTEC PHARMA LTD (NASDAQ), HARROW HEALTH INC (NASDAQ), ADAMAS PHARMACEUTICALS INC (NASDAQ), GOLDEN THROAT (HKEx), GALMED PHARMACEUTICALS LTD (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), FOAMIX PHARMACEUTICALS LTD (NASDAQ), OASMIA PHARMACEUTICAL AB ADR EACH REP 3 ORD SHS (NASDAQ), OPTHEA LIMITED (ASX), SANAI HEALTH GP (HKEx), DURECT CORP (NASDAQ), MEDIWOUND LTD (NASDAQ), CUMBERLAND PHARMACEUTICALS INC (NASDAQ), DOD (SET), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), ALTHEA GROUP HOLDINGS LTD (ASX), YSPSAH (Bursa), NEOS THERAPEUTICS INC (NASDAQ), VERONA PHARMA SPON ADR EACH REP 8 ORD SHS (NASDAQ), SCYNEXIS INC (NASDAQ), JILIN CHANGLONG (HKEx), PHARMAXIS (ASX), EAGLE HEALTH HOLDINGS LTD (ASX), AGILE THERAPEUTICS (NASDAQ), BOTANIX PHARMACEUTICALS LTD (ASX), INVION LTD (ASX), TIANDA PHARMA (HKEx), ORAMED PHARMACEUTICALS INC (NASDAQ), LANSEN PHARMA (HKEx), BIOLINE RX LTD SPON ADS EACH REPR 10 ORD SHS (NASDAQ), CTI BIOPHARMA CORP (NASDAQ), MGC PHARMACEUTICALS LTD (ASX), ACASTI PHARMA INC (NASDAQ), PLX PHARMA INC (NASDAQ), LIPOCINE INC (NASDAQ), TETRAPHASE PHARMACEUTICALS INC (NASDAQ), VIVUS INC (NASDAQ), KEMPHARM INC (NASDAQ), THC GLOBAL GROUP LTD (ASX), AMPIO PHARMACEUTICALS INC (NYSE American), MELINTA THERAPEUTICS INC (NASDAQ), VITA LIFE SCIENCES LIMITED (ASX), IDT AUSTRALIA LIMITED (ASX), REGULUS THERAPEUTICS INC (NASDAQ), ACRUX (ASX), COGSTATE (ASX), C HEALTH GP (HKEx), CYTRX CORP (NASDAQ), CASSAVA SCIENCES INC (NASDAQ), ANTISENSE THERAPEUTICS (ASX), EVOKE PHARMA INC (NASDAQ), MY SIZE INC (NASDAQ), BAYTACARE PHARM (HKEx), MYOS RENS TECHNOLOGY INC (NASDAQ), EYEGATE PHARMACEUTICALS INC (NASDAQ), CANNPAL ANIMAL THERAPEUTICS LTD (ASX), TONIX PHARMACEUTICALS HLDG CORP (NASDAQ), SONOMA PHARMACEUTICALS INC (NASDAQ), PHARMAUST LIMITED (ASX), Pyridam Farma Tbk (IDX), FLEX PHARMA INC (NASDAQ), RITTER PHARMACEUTICALS INC (NASDAQ), CONTRAVIR PHARMACEUTICALS INC (NASDAQ), LONGRUN TEA (HKEx), C ANIMAL HEALTH (HKEx), HUA HAN HEALTH (HKEx)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.005
-0.54 %
10 Days --0.040
-4.19 %
20 Days --0.095
-9.41 %
Medium Term Return 3 Months -+0.010
+1.10 %
6 Months -+0.050
+5.78 %
1 Year 0.030-0.275
-20.59 %
Long Term Return 2 Years 0.052+0.040
+10.51 %
3 Years 0.089+0.065
+18.12 %
5 Years 0.122-0.150
-2.63 %
Annualised Return Annualised --
-0.53 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.805 - 1.290 Change From 1 Year Low +0.110 % Change From 1 Year Low (%) +13.66
Change From 1 Year High -0.375 % Change From 1 Year High (%) -29.07
2 Years Range 0.805 - 1.290 Change From 2 Years Low +0.110 % Change From 2 Years Low (%) +13.66
Change From 2 Years High -0.375 % Change From 2 Years High (%) -29.07
5 Years Range 0.730 - 1.915 Change From 5 Years Low +0.185 % Change From 5 Years Low (%) +25.34
Change From 5 Years High -1.000 % Change From 5 Years High (%) -52.22
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

In the 1950s, with the China government's policy of merging state-owned pharmaceutical enterprises with the private sector, Tianjin Municipal Chinese Medicinal Materials Corpn (TMCM) merged and reorganised the various factories and stores in Tianjin. In December 1992, TMCM was converted from a state-owned enterprise to a company limited by shares whereby shares were issued to legal persons and its employees. In connection therewith, it was renamed Tianjin Traditional Chinese Medicine Group Co Ltd (TTCM). Following the corporatisation of the Company, the shares issued to the employees were traded at the Tianjin Securities Trading Centre.In conjunction with the proposed public offering, TTCM adopted its present name. Pursuant to the restructuring, it became the holding company for the Group.The Group's businesses cover a wide range of products including Chinese patent medicine, Chinese medicinal drinks, Chinese medicinal raw materials, biotechnology medicine, chemical raw material medicine and preparations, and nutritional and health products. It has over 800 medicinal products in over 20 types of formulations. The main products are Suxiao Jiuxin pill (used for treatment of heart disease), Huoxiang Zhengqi Soft capsule (used for treatment of intestines and stomach disease), Gengnian An (used for treatment of menopause symptoms), Zi Long Jin tablet (used for treatment of cancer), Xuefu Zhuyu capsule (used for treatment of diseases relating to heart and head blood vessel), Biqi capsule (used for treatment of rheumatism), Anfulong a-2b Interferon (used for increasing immunity ), Ge Lie Qi Te (used for treatment of diabetes), and Te Zi She Fu (used for diminishing inflammation).The holding company and ultimate holding company is Tianjin Pharmaceutical Hldgs, a company incorporated in Tianjin, China.

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2018 Dec 2018 Part 1(3.48 MB)
Annual Report 2017 Dec 2017 Part 1(3.65 MB)
Annual Report 2016 Dec 2016 Part 1(2.98 MB)
Annual Report 2015 Dec 2015 Part 1(2.25 MB)
Annual Report 2014 Dec 2014 Part 1(2.46 MB)
Annual Report 2013 Dec 2013 Part 1(1.87 MB)
Part 2(0.02 MB)
Part 3(0.02 MB)
Annual Report 2012 Dec 2012 Part 1(9.46 MB)
Annual Report 2011 Dec 2011 Part 1(11.18 MB)
Annual Report 2010 Dec 2010 Part 1(5.33 MB)
Annual Report 2009 Dec 2009 Part 1(0.75 MB)
Annual Report 2008 Dec 2008 Part 1(2.38 MB)
Annual Report 2007 Dec 2007 Part 1(1.33 MB)
Annual Report 2006 Dec 2006 Part 1(5.41 MB)
Annual Report 2005 Dec 2005 Part 1(0.68 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
21 May 2019 0.920 0.925 0.915 0.915 152,300 0.9205
20 May 2019 0.920 0.920 0.920 0.920 - -
17 May 2019 0.935 0.935 0.920 0.920 171,000 0.9254
16 May 2019 0.930 0.940 0.930 0.930 246,100 0.9344
15 May 2019 0.920 0.935 0.920 0.935 120,500 0.9303
14 May 2019 0.915 0.925 0.910 0.920 394,300 0.9182
13 May 2019 0.920 0.930 0.920 0.920 162,700 0.9228
10 May 2019 0.930 0.940 0.920 0.925 375,000 0.9306
09 May 2019 0.945 0.945 0.915 0.920 900,900 0.9283
08 May 2019 0.950 0.955 0.935 0.940 550,500 0.9457
07 May 2019 0.950 0.965 0.945 0.955 288,400 0.9553
06 May 2019 0.970 0.970 0.935 0.945 784,400 0.9507
03 May 2019 0.985 0.995 0.985 0.990 99,200 0.9873
02 May 2019 0.990 0.995 0.985 0.985 185,800 0.9874
30 Apr 2019 1.000 1.000 0.980 0.985 681,700 0.9876
29 Apr 2019 0.975 0.995 0.975 0.980 574,800 0.9873
26 Apr 2019 0.980 0.985 0.970 0.975 194,100 0.9784
25 Apr 2019 1.010 1.020 0.970 0.970 1,717,800 0.9946
24 Apr 2019 1.010 1.020 1.000 1.020 540,900 1.0102
23 Apr 2019 1.010 1.030 0.995 1.010 668,500 1.0089
22 Apr 2019 1.030 1.030 1.010 1.020 196,900 1.0159
18 Apr 2019 1.030 1.030 1.020 1.020 310,300 1.0273
Summary
Current 2 Weeks
(08 May 2019 to 21 May 2019)
0.950 0.955 0.910 0.915 3,073,300 -
Previous 2 Weeks
(23 Apr 2019 to 07 May 2019)
1.010 1.030 0.910 0.955 5,735,600 -
4 Weeks from
(25 Mar 2019 to 22 Apr 2019)
0.905 0.955 0.890 1.020 15,707,100 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.